Linked Life Data

1892770

Source:http://linkedlifedata.com/resource/pubmed/id/1892770

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1892770rdf:typepubmed:Citationlld:pubmed
pubmed-article:1892770lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:1892770lifeskim:mentionsumls-concept:C0220645lld:lifeskim
pubmed-article:1892770lifeskim:mentionsumls-concept:C0025241lld:lifeskim
pubmed-article:1892770lifeskim:mentionsumls-concept:C0444956lld:lifeskim
pubmed-article:1892770lifeskim:mentionsumls-concept:C0054889lld:lifeskim
pubmed-article:1892770lifeskim:mentionsumls-concept:C0077964lld:lifeskim
pubmed-article:1892770lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:1892770lifeskim:mentionsumls-concept:C0280062lld:lifeskim
pubmed-article:1892770lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:1892770lifeskim:mentionsumls-concept:C0449445lld:lifeskim
pubmed-article:1892770lifeskim:mentionsumls-concept:C0439831lld:lifeskim
pubmed-article:1892770lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:1892770pubmed:issue2lld:pubmed
pubmed-article:1892770pubmed:dateCreated1991-10-22lld:pubmed
pubmed-article:1892770pubmed:abstractTextForty-three children with malignant soft tissue sarcomas (IRS Groups II-IV) were treated with rapid dose delivery chemotherapy protocol comprising six courses of vincristine, adriamycin and cyclophosphamide, given in most cases within 8 weeks (Rapid VAC). This was followed in 36 patients by high dose melphalan with autologous bone marrow rescue. Twenty-six patients also received irradiation to the site of primary tumour. The Rapid VAC regimen was well tolerated and largely administered as an out-patient. There was one toxic death which occurred 2 months after high dose melphalan due to a combination of infection and possible anthracycline cardiomyopathy. Stages were, (Intergroup Rhabdomyosarcoma Study (IRS) system) Group, Group II--four patients. Group III--27 patients and Group IV--12 patients; International Society of Paediatric Oncology (SIOP) staging, Stage I--11, Stage II--13, Stage III--7, Stage IV--12. Actuarial survival at 5 years for all stages is 57% and event free survival 44%. For patients with non-metastatic diseases, 62% and 53% respectively. This treatment strategy utilises the philosophy of rapid drug delivery with high dose consolidation and enables all chemotherapy to be finished within a 4 month period. In general, a conservative approach was applied to both radiation and surgery to minimise late sequelae related to these treatment modalities. Although the small number of high risk patients in this study limits conclusions regarding efficacy in these subgroups the overall results with this regimen appear to be comparable to that with other approaches.lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:languageenglld:pubmed
pubmed-article:1892770pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:citationSubsetIMlld:pubmed
pubmed-article:1892770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1892770pubmed:statusMEDLINElld:pubmed
pubmed-article:1892770pubmed:monthAuglld:pubmed
pubmed-article:1892770pubmed:issn0007-0920lld:pubmed
pubmed-article:1892770pubmed:authorpubmed-author:BarretoFFlld:pubmed
pubmed-article:1892770pubmed:authorpubmed-author:McElwainT JTJlld:pubmed
pubmed-article:1892770pubmed:authorpubmed-author:MellerS TSTlld:pubmed
pubmed-article:1892770pubmed:authorpubmed-author:PinkertonC...lld:pubmed
pubmed-article:1892770pubmed:authorpubmed-author:AshleySSlld:pubmed
pubmed-article:1892770pubmed:authorpubmed-author:TaitDDlld:pubmed
pubmed-article:1892770pubmed:authorpubmed-author:Groot-LoonenJ...lld:pubmed
pubmed-article:1892770pubmed:issnTypePrintlld:pubmed
pubmed-article:1892770pubmed:volume64lld:pubmed
pubmed-article:1892770pubmed:ownerNLMlld:pubmed
pubmed-article:1892770pubmed:authorsCompleteYlld:pubmed
pubmed-article:1892770pubmed:pagination381-5lld:pubmed
pubmed-article:1892770pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:1892770pubmed:meshHeadingpubmed-meshheading:1892770-...lld:pubmed
pubmed-article:1892770pubmed:meshHeadingpubmed-meshheading:1892770-...lld:pubmed
pubmed-article:1892770pubmed:meshHeadingpubmed-meshheading:1892770-...lld:pubmed
pubmed-article:1892770pubmed:meshHeadingpubmed-meshheading:1892770-...lld:pubmed
pubmed-article:1892770pubmed:meshHeadingpubmed-meshheading:1892770-...lld:pubmed
pubmed-article:1892770pubmed:meshHeadingpubmed-meshheading:1892770-...lld:pubmed
pubmed-article:1892770pubmed:meshHeadingpubmed-meshheading:1892770-...lld:pubmed
pubmed-article:1892770pubmed:meshHeadingpubmed-meshheading:1892770-...lld:pubmed
pubmed-article:1892770pubmed:meshHeadingpubmed-meshheading:1892770-...lld:pubmed
pubmed-article:1892770pubmed:year1991lld:pubmed
pubmed-article:1892770pubmed:articleTitleRapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas.lld:pubmed
pubmed-article:1892770pubmed:affiliationChildren's Unit, Royal Marsden Hospital, Sutton, UK.lld:pubmed
pubmed-article:1892770pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1892770lld:pubmed